(VIANEWS) - Albemarle (ALB), Banner Corporation (BANR), The Ensign Group (ENSG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Albemarle (ALB)
193.1% sales growth and 5.66% return on equity
Albemarle Corporation is a global manufacturer and marketer of engineered specialty chemicals. The company operates in three main segments, Lithium and Bromine. Lithium offers lithium compounds such as lithium carbonate and lithium hydroxide. It also has lithium specialties. The company also offers cesium products to the pharmaceutical and chemical industries, zirconium and barium, as well as titanium products for pyrotechnical uses, including airbag initiators, technical services for handling reactive lithium products, and recycling of lithium-containing byproducts. Bromine offers specialty chemicals such as bromine, inorganic and elemental bromides; brominated powdered active carbon and other bromine fine chemical for chemical synthesis, oil well drilling, completion fluids, water purification and mercury control. It also provides bromine-based fire protection solutions. Catalysts provides hydroprocessing and isomerization as well as fluidized catalysts for cracking and additives. It serves markets such as energy storage, petroleum refining and consumer electronics. Albemarle Corporation was established in 1887. It is located in Charlotte, North Carolina.
Earnings per Share
Albemarle's trailing twelve-month EPS is $3.52.
PE Ratio
Albemarle's trailing 12-month price-earnings ratio is 60.72. The purchaser of the shares is investing $60.72 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is an indicator of the business' profitability relative to shareholders' equity, was 5.66%.Moving Average
Albemarle's worth is way under its 50-day moving average of $273.25 and way below its 200-day moving average of $244.23.Volume
Today's last reported volume for Albemarle is 1729040 which is 17.78% above its average volume of 1468020.
Annual Top and Bottom Value
Albemarle stock's value is $213.75 as of 15:22 EST. This price is way below its 52 week high of $334.55, and much higher than its 52 week low of $169.93.
Sales Growth
Albemarle's sales growth is 192.4% for the present quarter and 193.1% for the next.
2. Banner Corporation (BANR)
30.4% sales growth and 12.42% return on equity
Banner Corporation operates as the bank holding company for Banner Bank that provide commercial banking and financial products and services to individuals, businesses, and public sector entities in the United States. It accepts various deposit instruments, including interest-bearing and non-interest-bearing checking accounts, money market deposit accounts, regular savings accounts, and certificates of deposit, as well as treasury management services and retirement savings plans. The company also provides commercial real estate loans, including owner-occupied, investment properties, and multifamily residential real estate loans; construction, land, and land development loans; residential mortgage loans; commercial business loans; agricultural loans; and consumer and other loans, such as home equity lines of credit, automobile, and boat and recreational vehicle loans, as well as loans secured by deposit accounts. In addition, it engages in the mortgage banking operations through the origination and sale of one-to four-family and multi-family residential loans, as well as small business administration loans. Further, the company provides electronic and digital banking services. As of December 31, 2021, it operated 150 branch offices and 18 loan production offices located in Washington, Oregon, California, Idaho, and Utah. Banner Corporation was founded in 1890 and is headquartered in Walla Walla, Washington.
Earnings Per Share
As for profitability, Banner Corporation has a trailing twelve months EPS of $5.53.
PE Ratio
Banner Corporation has a trailing twelve months price to earnings ratio of 11.43. Meaning, the purchaser of the share is investing $11.43 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.42%.Sales Growth
Banner Corporation has experienced a 26.4% and 30.4% sales increase in the current quarter.
3. The Ensign Group (ENSG)
13.5% sales growth and 19.72% return on equity
The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company operates in two segments, Skilled Services and Real Estate. The company offers skilled services, which include short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; and physical, occupational, and speech therapies and other rehabilitative and healthcare services. It also provides standard services, such as room and board, special nutritional programs, social, recreational, entertainment, and other services. In addition, the company offers senior living, as well as mobile diagnostics services; leases real estate properties; and provides other ancillary services consisting of digital x-ray, ultrasound, electrocardiogram, laboratory, sub-acute, and patient transportation services to people in their homes or at long-term care facilities. As of April 4, 2022, it operated 252 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
Earnings Per Share
As for profitability, The Ensign Group has a trailing twelve months EPS of $3.19.
PE Ratio
The Ensign Group has a trailing twelve months price to earnings ratio of 29.65. Meaning, the purchaser of the share is investing $29.65 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.72%.Dividend Yield
According to Morningstar, Inc., Sep 28 2022 will be the next distribution. The forward dividend rate and yield are 0.22 percent and 0.24% respectively.
Yearly Top and Bottom Value
The Ensign Group's stock is valued at $94.61 at 15:24 EST, below its 52-week high of $97.42 and way above its 52-week low of $70.29.
Moving Average
The Ensign Group's worth is higher than its 50-day moving average of $92.38 and way above its 200-day moving average of $84.59.4. Incyte Corporation (INCY)
12.7% sales growth and 23.76% return on equity
Incyte Corporation is a biopharmaceutical firm that focuses on developing, commercializing, and distributing proprietary therapeutics throughout the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. Parsaclisib is also being developed by the company. It is currently in phase II clinical trials for marginal zone lymphoma and follicular lymphoma. It also develops Retifanlimab, which is currently in Phase 2 clinical trials in MSI-high endometrial carcinoma, merkel cells carcinoma and anal carcinoma. There are collaboration agreements with Novartis International Pharmaceutical Ltd., Eli Lilly and Company, Agenus Inc., Calithera Biosciences, Inc., MacroGenics, Inc., Syros Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc., Innovent Biologics, Inc., Syros Pharmaceuticals, Inc., Innovent Biologics, Inc., Zai Lab Limited, Cellenkos, Inc., and Nimble Therapeutics. These collaborations include clinical collaborations AG and tasitamab, plamotamab, lenalidomide, follicular, relapsed, plamotamab, refractory, follicular, follicular, follicular, follicular, follicular, follicular, refractory, follicular, tamab, fasitab, and lenalidomide, Inc. It was founded in 1991. The headquarters are in Wilmington, Delaware.
Earnings per Share
Incyte Corporation's trailing twelve-month EPS is $-1.36.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability of a company relative to shareholders' equity, was 23.76%.Annual Top and Bottom Value
At 15:24 EST Incyte Corporation stock was valued at $79.63. This is lower than the 52-week high at $84.86, and much higher than the 52-week low at $65.07.
Earnings before Interest, Taxes and Depreciation
Incyte Corporation has a 73.2 EBITDA.
5. Valero Energy (VLO)
9.7% sales growth and 35.49% return on equity
Valero Energy Corporation manufactures, markets, and sells transportation fuels and petrochemical products in the United States, Canada, the United Kingdom, Ireland, and internationally. The company operates through three segments: Refining, Renewable Diesel, and Ethanol. It produces conventional, premium, and reformulated gasolines; gasoline meeting the specifications of the California Air Resources Board (CARB); diesel fuels, and low-sulfur and ultra-low-sulfur diesel fuels; CARB diesel; other distillates; jet fuels; blendstocks; and asphalts, petrochemicals, lubricants, and other refined petroleum products, as well as sells lube oils and natural gas liquids. As of December 31, 2021, the company owned 15 petroleum refineries with a combined throughput capacity of approximately 3.2 million barrels per day; and 12 ethanol plants with a combined ethanol production capacity of approximately 1.6 billion gallons per year. It sells its refined products through wholesale rack and bulk markets; and through approximately 7,000 outlets under the Valero, Beacon, Diamond Shamrock, Shamrock, Ultramar, and Texaco brands. The company also produces and sells ethanol, dry distiller grains, syrup, and inedible corn oil primarily to animal feed customers. In addition, it owns and operates crude oil and refined petroleum products pipelines, terminals, tanks, marine docks, truck rack bays, and other logistics assets; and owns and operates a plant that processes animal fats, used cooking oils, and inedible distillers corn oils into renewable diesel. The company was formerly known as Valero Refining and Marketing Company and changed its name to Valero Energy Corporation in August 1997. Valero Energy Corporation was founded in 1980 and is headquartered in San Antonio, Texas.
Earnings Per Share
As for profitability, Valero Energy has a trailing twelve months EPS of $-0.69.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 35.49%.Yearly Top and Bottom Value
Valero Energy's stock is valued at $120.19 at 15:26 EST, way under its 52-week high of $146.81 and way higher than its 52-week low of $65.13.